Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Cancer Radiother ; 28(3): 236-241, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38871605

RESUMO

PURPOSE: Many cancer patients develop bone metastases, however the prognosis of overall survival differs. To provide an optimal treatment for these patients, especially towards the end of life, a reliable prediction of survival is needed. The goal of this study was to find new clinical factors in relation to overall survival. MATERIALS AND METHODS: Prospectively 22 clinical factors were collected from 734 patients. The Kaplan-Meier and Cox regression models were used. RESULTS: Most patients were diagnosed with lung cancer (29%), followed by prostate (19.8%) and breast cancer (14.7%). Median overall survival was 6.4months. Fourteen clinical factors showed significance in the univariate analyses. In the multivariate analyses 6 factors were found to be significant for the overall survival: Karnofsky performance status, primary tumor, gender, total organs affected, morphine use and systemic treatment options after radiotherapy. CONCLUSION: Morphine use and systemic treatment options after radiotherapy, Karnofsky performance status, primary tumor, gender and total organs affected are strong prediction factors on overall survival after palliative radiotherapy in patients with bone metastasis. These factors are easily applicable in the clinic.


Assuntos
Neoplasias Ósseas , Avaliação de Estado de Karnofsky , Cuidados Paliativos , Humanos , Masculino , Neoplasias Ósseas/secundário , Neoplasias Ósseas/radioterapia , Neoplasias Ósseas/mortalidade , Feminino , Prognóstico , Idoso , Pessoa de Meia-Idade , Estudos Prospectivos , Idoso de 80 Anos ou mais , Adulto , Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Neoplasias da Próstata/radioterapia , Neoplasias da Próstata/patologia , Neoplasias da Próstata/mortalidade , Morfina/uso terapêutico , Neoplasias da Mama/patologia , Neoplasias da Mama/radioterapia , Neoplasias da Mama/mortalidade , Estimativa de Kaplan-Meier , Fatores Sexuais , Analgésicos Opioides/uso terapêutico
2.
J Bone Joint Surg Am ; 100(3): 196-204, 2018 Feb 07.
Artigo em Inglês | MEDLINE | ID: mdl-29406340

RESUMO

BACKGROUND: A survival estimation for patients with symptomatic long bone metastases (LBM) is crucial to prevent overtreatment and undertreatment. This study analyzed prognostic factors for overall survival and developed a simple, easy-to-use prognostic model. METHODS: A multicenter retrospective study of 1,520 patients treated for symptomatic LBM between 2000 and 2013 at the radiation therapy and/or orthopaedic departments was performed. Primary tumors were categorized into 3 clinical profiles (favorable, moderate, or unfavorable) according to an existing classification system. Associations between prognostic variables and overall survival were investigated using the Kaplan-Meier method and multivariate Cox regression models. The discriminatory ability of the developed model was assessed with the Harrell C-statistic. The observed and expected survival for each survival category were compared on the basis of an external cohort. RESULTS: Median overall survival was 7.4 months (95% confidence interval [CI], 6.7 to 8.1 months). On the basis of the independent prognostic factors, namely the clinical profile, Karnofsky Performance Score, and presence of visceral and/or brain metastases, 12 prognostic categories were created. The Harrell C-statistic was 0.70. A flowchart was developed to easily stratify patients. Using cutoff points for clinical decision-making, the 12 categories were narrowed down to 4 categories with clinical consequences. Median survival was 21.9 months (95% CI, 18.7 to 25.1 months), 10.5 months (95% CI, 7.9 to 13.1 months), 4.6 months (95% CI, 3.9 to 5.3 months), and 2.2 months (95% CI, 1.8 to 2.6 months) for the 4 categories. CONCLUSIONS: This study presents a model to easily stratify patients with symptomatic LBM according to their expected survival. The simplicity and clarity of the model facilitate and encourage its use in the routine care of patients with LBM, to provide the most appropriate treatment for each individual patient. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.


Assuntos
Neoplasias Ósseas/mortalidade , Neoplasias Ósseas/secundário , Análise de Sobrevida , Idoso , Neoplasias Ósseas/terapia , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Modelos Estatísticos , Prognóstico , Estudos Retrospectivos
3.
Allergy ; 64(3): 398-405, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19120070

RESUMO

BACKGROUND: The association between cigarette smoke exposure and allergic airway disease is a matter for debate. We sought to investigate in an in vitro system whether active smoking reduces the integrity and barrier function of the respiratory epithelium and thus facilitates allergen penetration. METHODS: We cultured the human bronchial epithelial cell line 16HBE14o- in a transwell culture system as a surrogate for the intact respiratory epithelium. The cell monolayer was exposed to standardized cigarette smoke extract (CSE). The extent and effects of trans-epithelial allergen penetration were measured using 125I-labelled purified major respiratory allergens (rBet v 1, rPhl p 5 and rDer p 2) and histamine release experiments. RESULTS: Exposure of cells to concentrations of CSE similar to those found in smokers induced the development of para-cellular gaps and a decrease in trans-epithelial resistance. CSE exposure induced a more than threefold increase in allergen penetration. Increased subepithelial allergen concentrations provoked a substantial augmentation of histamine release from sensitized basophils. CONCLUSIONS: Our results indicate that cigarette smoke is a potent factor capable of reducing the barrier function of the respiratory epithelium for allergens and may contribute to increased allergic inflammation, exacerbation of allergic disease and boosting of IgE memory.


Assuntos
Alérgenos/metabolismo , Permeabilidade da Membrana Celular/efeitos dos fármacos , Nicotiana/efeitos adversos , Mucosa Respiratória/metabolismo , Alérgenos/imunologia , Linhagem Celular , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Permeabilidade da Membrana Celular/imunologia , Citocinas , Citometria de Fluxo , Liberação de Histamina/efeitos dos fármacos , Humanos , Imuno-Histoquímica , Mucosa Respiratória/imunologia , Fumaça
4.
Am J Transplant ; 8(10): 2025-36, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18828766

RESUMO

Allogeneic bone marrow transplantation (BMT) under costimulation blockade allows induction of mixed chimerism and tolerance without global T-cell depletion (TCD). The mildest such protocols without recipient cytoreduction, however, require clinically impracticable bone marrow (BM) doses. The successful use of mobilized peripheral blood stem cells (PBSC) instead of BM in such regimens would provide a substantial advance, allowing transplantation of higher doses of hematopoietic donor cells. We thus transplanted fully allogeneic murine granulocyte colony-stimulating factor (G-CSF) mobilized PBSC under costimulation blockade (anti-CD40L and CTLA4Ig). Unexpectedly, PBSC did not engraft, even when very high cell doses together with nonmyeloablative total body irradiation (TBI) were used. We show that, paradoxically, T cells contained in the donor PBSC triggered rejection of the transplanted donor cells. Rejection of donor BM was also triggered by the cotransplantation of unmanipulated donor T cells isolated from naïve (nonmobilized) donors. Donor-specific transfusion and transient immunosuppression prevented PBSC-triggered rejection and mixed chimerism and tolerance were achieved, but graft-versus-host disease (GVHD) occurred. The combination of in vivo TCD with costimulation blockade prevented rejection and GVHD. Thus, if allogeneic PBSC are transplanted instead of BM, costimulation blockade alone does not induce chimerism and tolerance without unacceptable GVHD-toxicity, and the addition of TCD is required for success.


Assuntos
Células da Medula Óssea/citologia , Tolerância Imunológica , Transplante de Células-Tronco/métodos , Células-Tronco/citologia , Quimeras de Transplante/imunologia , Animais , Células da Medula Óssea/metabolismo , Feminino , Citometria de Fluxo/métodos , Fator Estimulador de Colônias de Granulócitos/metabolismo , Células-Tronco Hematopoéticas/citologia , Imunossupressores/uso terapêutico , Camundongos , Camundongos Endogâmicos C57BL , Linfócitos T/metabolismo , Tolerância ao Transplante
5.
Ned Tijdschr Geneeskd ; 143(12): 630-3, 1999 Mar 20.
Artigo em Holandês | MEDLINE | ID: mdl-10321290

RESUMO

A 85-year-old woman presented clinically with paronychia. Treatment for this was uneffective, however. Finally, the diagnosis was Bowen's disease of the nail bed with underlying invasive squamous cell carcinoma. Treatment consisted of a subcapital amputation through the middle phalanx. Subungual tumors often appear to be a diagnostic problem because of their benign presentation. Every longstanding nail bed disease that does not respond to therapy needs to be biopted.


Assuntos
Doença de Bowen/diagnóstico , Carcinoma de Células Escamosas/diagnóstico , Doenças da Unha/diagnóstico , Neoplasias Primárias Múltiplas/diagnóstico , Neoplasias Cutâneas/diagnóstico , Idoso , Idoso de 80 Anos ou mais , Amputação Cirúrgica , Doença de Bowen/cirurgia , Carcinoma de Células Escamosas/cirurgia , Erros de Diagnóstico , Feminino , Dedos/cirurgia , Humanos , Doenças da Unha/cirurgia , Neoplasias Primárias Múltiplas/cirurgia , Paroniquia/diagnóstico , Neoplasias Cutâneas/cirurgia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA